TY - JOUR
T1 - A new lateral flow plasmonic biosensor based on gold-viral biomineralized nanozyme for on-site intracellular glutathione detection to evaluate drug-resistance level
AU - Pang, Hao Han
AU - Ke, Yong Chen
AU - Li, Nan Si
AU - Chen, Ying Tzu
AU - Huang, Chiung Yin
AU - Wei, Kuo Chen
AU - Yang, Hung Wei
N1 - Funding Information:
This work was financially supported by the Ministry of Science and Technology, Chang Gung Memorial Hospital, and National Health Research Institutes, Taiwan (ROC), whom we thank for the financial assistance provided (MOST106-2628-E-110-001-MY3, MOST106-2628-B-110-MY4, MOST108-2314-B-182-019-MY2, CORPG3I0111, NHRI-EX108-10502NI). Furthermore, we would like to thank the Chang Gung Memorial Hospital Microscopy Core Laboratory for their TEM and SEM assistance.
Funding Information:
This work was financially supported by the Ministry of Science and Technology , Chang Gung Memorial Hospital , and National Health Research Institutes , Taiwan (ROC), whom we thank for the financial assistance provided ( MOST106-2628-E-110-001-MY3 , MOST106-2628-B-110-MY4 , MOST108-2314-B-182-019-MY2 , CORPG3I0111 , NHRI-EX108-10502NI ). Furthermore, we would like to thank the Chang Gung Memorial Hospital Microscopy Core Laboratory for their TEM and SEM assistance.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) cells would have abnormal redox status due to bio-thiols, like glutathione (GSH), which constitute the most crucial defense system that protects cells from therapeutic agents. Current strategies for GSH detection often require sophisticated instruments that may not be available in laboratories with fewer resources. Here, we circumvent this problem by introducing a lateral flow plasmonic biosensor (LFPB) based on gold-viral biomineralized nanoclusters (AuVCs) as nanozymes that enables the detection of a few molecules with the naked eye and quantified by an auto-analysis software. The GSH level controls the growth of gold nanoparticles (AuNPs) and generates coloured patterns with distinct tonality, which are then auto-analyzed to calculate the GSH concentrations by smartphone with an auto-analysis software. Under the optimized conditions, grayscale value plotted against GSH concentration exhibited a linear relationship within the range of 25–500 μM with a limit of detection (LoD) of 9.80 μM and highly positive correlation between detected GSH level and TMZ drug-resistance level in GBM cells. This excellent property allowed our approach to be used for on-site determination of GSH levels in a rapid (i.e., within 30 min), simple (i.e., auto-analysis software), and cost-effective process (i.e., instrument-free) for cancer precision therapy.
AB - Temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) cells would have abnormal redox status due to bio-thiols, like glutathione (GSH), which constitute the most crucial defense system that protects cells from therapeutic agents. Current strategies for GSH detection often require sophisticated instruments that may not be available in laboratories with fewer resources. Here, we circumvent this problem by introducing a lateral flow plasmonic biosensor (LFPB) based on gold-viral biomineralized nanoclusters (AuVCs) as nanozymes that enables the detection of a few molecules with the naked eye and quantified by an auto-analysis software. The GSH level controls the growth of gold nanoparticles (AuNPs) and generates coloured patterns with distinct tonality, which are then auto-analyzed to calculate the GSH concentrations by smartphone with an auto-analysis software. Under the optimized conditions, grayscale value plotted against GSH concentration exhibited a linear relationship within the range of 25–500 μM with a limit of detection (LoD) of 9.80 μM and highly positive correlation between detected GSH level and TMZ drug-resistance level in GBM cells. This excellent property allowed our approach to be used for on-site determination of GSH levels in a rapid (i.e., within 30 min), simple (i.e., auto-analysis software), and cost-effective process (i.e., instrument-free) for cancer precision therapy.
UR - http://www.scopus.com/inward/record.url?scp=85086464218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086464218&partnerID=8YFLogxK
U2 - 10.1016/j.bios.2020.112325
DO - 10.1016/j.bios.2020.112325
M3 - Article
C2 - 32729474
AN - SCOPUS:85086464218
SN - 0956-5663
VL - 165
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
M1 - 112325
ER -
